Mangalam Drugs & Organics Limited

NSEI:MANGALAM Stock Report

Market Cap: ₹1.6b

Mangalam Drugs & Organics Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Govardhan Dhoot

Chief executive officer

₹2.0m

Total compensation

CEO salary percentage100.0%
CEO tenure28.8yrs
CEO ownership6.8%
Management average tenure10.3yrs
Board average tenure6.9yrs

Recent management updates

Recent updates

Additional Considerations Required While Assessing Mangalam Drugs & Organics' (NSE:MANGALAM) Strong Earnings

Nov 22
Additional Considerations Required While Assessing Mangalam Drugs & Organics' (NSE:MANGALAM) Strong Earnings

Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues Are Not Doing Enough For Some Investors

Aug 13
Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues Are Not Doing Enough For Some Investors

A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

May 23
A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Little Excitement Around Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues As Shares Take 25% Pounding

Mar 28
Little Excitement Around Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues As Shares Take 25% Pounding

Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Shares Lagging The Industry But So Is The Business

Feb 07
Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Shares Lagging The Industry But So Is The Business

Estimating The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Oct 20
Estimating The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?

Mar 29
Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?

These 4 Measures Indicate That Mangalam Drugs & Organics (NSE:MANGALAM) Is Using Debt Extensively

May 31
These 4 Measures Indicate That Mangalam Drugs & Organics (NSE:MANGALAM) Is Using Debt Extensively

A Look At The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Apr 06
A Look At The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

We Think Mangalam Drugs & Organics (NSE:MANGALAM) Is Taking Some Risk With Its Debt

Jan 03
We Think Mangalam Drugs & Organics (NSE:MANGALAM) Is Taking Some Risk With Its Debt

Here's Why Mangalam Drugs & Organics (NSE:MANGALAM) Can Manage Its Debt Responsibly

May 23
Here's Why Mangalam Drugs & Organics (NSE:MANGALAM) Can Manage Its Debt Responsibly

Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?

Jan 04
Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?

Do Its Financials Have Any Role To Play In Driving Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Stock Up Recently?

Nov 12
Do Its Financials Have Any Role To Play In Driving Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Stock Up Recently?

A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Sep 20
A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Does Mangalam Drugs & Organics's (NSE:MANGALAM) Statutory Profit Adequately Reflect Its Underlying Profit?

Aug 05
Does Mangalam Drugs & Organics's (NSE:MANGALAM) Statutory Profit Adequately Reflect Its Underlying Profit?

We Think Mangalam Drugs & Organics (NSE:MANGALAM) Can Stay On Top Of Its Debt

Jul 01
We Think Mangalam Drugs & Organics (NSE:MANGALAM) Can Stay On Top Of Its Debt

CEO Compensation Analysis

How has Govardhan Dhoot's remuneration changed compared to Mangalam Drugs & Organics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹94m

Jun 30 2024n/an/a

₹31m

Mar 31 2024₹2m₹2m

-₹91m

Dec 31 2023n/an/a

-₹170m

Sep 30 2023n/an/a

-₹171m

Jun 30 2023n/an/a

-₹113m

Mar 31 2023₹2m₹2m

₹13m

Dec 31 2022n/an/a

₹123m

Sep 30 2022n/an/a

₹159m

Jun 30 2022n/an/a

₹182m

Mar 31 2022₹2m₹2m

₹197m

Dec 31 2021n/an/a

₹151m

Sep 30 2021n/an/a

₹175m

Jun 30 2021n/an/a

₹241m

Mar 31 2021₹2mn/a

₹280m

Dec 31 2020n/an/a

₹309m

Sep 30 2020n/an/a

₹261m

Jun 30 2020n/an/a

₹158m

Mar 31 2020₹5m₹2m

₹83m

Dec 31 2019n/an/a

-₹28m

Sep 30 2019n/an/a

-₹89m

Jun 30 2019n/an/a

-₹80m

Mar 31 2019₹2m₹2m

-₹80m

Dec 31 2018n/an/a

₹10m

Sep 30 2018n/an/a

₹114m

Jun 30 2018n/an/a

₹164m

Mar 31 2018₹2m₹2m

₹199m

Compensation vs Market: Govardhan's total compensation ($USD23.16K) is below average for companies of similar size in the Indian market ($USD41.59K).

Compensation vs Earnings: Govardhan's compensation has been consistent with company performance over the past year.

CEO

Govardhan Dhoot (71 yo)

28.8yrs

Tenure

₹2,006,000

Compensation

Shri Govardhan Murlidhar Dhoot serves as the Chairman of the Board and Managing Director at Mangalam Drugs & Organics Limited and has been its Executive Director since April 16, 1996.

Leadership Team

NamePositionTenureCompensationOwnership
Govardhan Dhoot
Chairman & MDno data₹2.01m6.81%
₹ 110.6m
Kamal Vashi
Presidentno data₹7.07mno data
Ajay Samant
Chief Financial Officer10.3yrs₹2.69mno data
Krishnapriya Nawal
Chief Operating Officerno data₹2.97mno data
Brijmohan Dhoot
Whole-Time Directorno data₹613.00k3.57%
₹ 58.0m
Anuradha Pandey
Company Secretary & Compliance Officerless than a yearno datano data
Yaduraj Dhoot
Head of Purchaseno datano data0.040%
₹ 650.2k
Mansi Pathak
Senior Manager4.2yrsno datano data
Rakesh Srivastava
General Manager20.1yrsno datano data
Bhanvesh Naik
General Manager18.3yrsno datano data

10.3yrs

Average Tenure

45yo

Average Age

Experienced Management: MANGALAM's management team is seasoned and experienced (10.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Govardhan Dhoot
Chairman & MD28.8yrs₹2.01m6.81%
₹ 110.6m
Brijmohan Dhoot
Whole-Time Director9.7yrs₹613.00k3.57%
₹ 58.0m
Rukmesh Dhandhania
Independent Director7.2yrs₹26.00kno data
Nidhi Mundada
Non-Executive Independent Director6.7yrs₹32.00kno data
Praveen Saxena
Independent Non-Executive Director3.8yrs₹16.00kno data
Rakesh Milwani
Non-Executive Non-Independent Director2.8yrs₹12.00kno data

6.9yrs

Average Tenure

69yo

Average Age

Experienced Board: MANGALAM's board of directors are considered experienced (6.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 23:49
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mangalam Drugs & Organics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vijay MadunalaFirstCall Research